Search by Drug Name or NDC
NDC 70720-0950-36 ZOLADEX 3.6 mg/1 Details
ZOLADEX 3.6 mg/1
ZOLADEX is a SUBCUTANEOUS IMPLANT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by TerSera Therapeutics LLC. The primary component is GOSERELIN ACETATE.
MedlinePlus Drug Summary
Goserelin implant is used in combination with radiation therapy and other medications to treat localized prostate cancer and is used alone to treat the symptoms associated with advanced prostate cancer. It is also used to treat advanced breast cancer in certain women. It is also used to manage endometriosis (a condition in which the type of tissue that lines the uterus [womb] grows in other areas of the body and causes pain, heavy or irregular menstruation [periods], and other symptoms) and to help with the treatment of abnormal bleeding of the uterus. Goserelin implant is in a class of medications called gonadotropin-releasing hormone (GnRH) agonists. It works by decreasing the amount of certain hormones in the body.
Related Packages: 70720-0950-36Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Goserelin Implant
Product Information
| NDC | 70720-0950 |
|---|---|
| Product ID | 70720-950_71b8db45-e40e-4de5-bdab-c409c968c271 |
| Associated GPIs | 21405005102310 |
| GCN Sequence Number | 044962 |
| GCN Sequence Number Description | goserelin acetate IMPLANT 3.6 MG SUBCUT |
| HIC3 | V1O |
| HIC3 Description | ANTINEOPLASTIC LHRH(GNRH) AGONIST,PITUITARY SUPPR. |
| GCN | 84591 |
| HICL Sequence Number | 021114 |
| HICL Sequence Number Description | GOSERELIN ACETATE |
| Brand/Generic | Brand |
| Proprietary Name | ZOLADEX |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | goserelin |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | IMPLANT |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 3.6 |
| Active Ingredient Units | mg/1 |
| Substance Name | GOSERELIN ACETATE |
| Labeler Name | TerSera Therapeutics LLC |
| Pharmaceutical Class | Gonadotropin Releasing Hormone Receptor Agonist [EPC], Gonadotropin Releasing Hormone Receptor Agonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA019726 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 70720-0950-36 (70720095036)
| NDC Package Code | 70720-950-36 |
|---|---|
| Billing NDC | 70720095036 |
| Package | 1 POUCH in 1 CARTON (70720-950-36) / 1 SYRINGE in 1 POUCH / 1 IMPLANT in 1 SYRINGE |
| Marketing Start Date | 2018-03-31 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |